Log in  First Connection? Edition EN | FR

Typhoid  Archives

Diseases: Chikungunya | Cholera | Dengue Fever | Diphteria | Hepatitis A | Hepatitis B | Japanese Encephalitis | Lyme Disease | Malaria | Rabies | Tick Borne Encephalitis (TBE) | Travellers Diarrhea | Typhoid | Yellow Fever | Zika | Editorial (FR)
Categories: Editorial | Experts Opinions | Congress Highlights

 Typhoid
Exploring the antimicrobial efficacy of Manuka honey against multidrug-resistant and extensively drug-resistant Salmonella Typhi causing septicemia in Pakistan

Published on 26/06/2025 |  Original article (Full-text)  | Iqra Bashir et al. | Future Microbiology 2024; 19(16): 1377-87 4 min.

To determine the efficacy of manuka honey against multidrug-resistant (MDR) and extensively drug-resistant (XDR) clinical strains of SalmonellaTyphi. Materials & methods: Clinical isolates were processed using the Bactec blood culture system, identification and...

HTML version PDF version  Print abstract

 Typhoid
Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation

Published on 26/06/2025 |  Original article (Full-text)  | Emary, Kate et al. | Vaccine 2025; 55(In progress): 127008 4 min.

Invasive disease caused by non-typhoidal Salmonella serovars (iNTS) occurs with increased risk in the presence of other comorbidities such as malaria, HIV, malnutrition, anaemia and sickle cell disease. While infection with non-typhoidal (NTS) serovars often results in self-limited enterocolitis in high-income...

HTML version PDF version  Print abstract

 Typhoid
Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers

Published on 26/06/2025 |  Original article (Full-text)  | Dipesh Tamrakar et al. | Human vaccines & immunotherapeutics 2024; 20(1): 4 min.

Typhoid fever is a significant public health concern with most of the sufferers between 15 and 25 y of age in Nepal. We undertook this study to demonstrate Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT) conjugate vaccine which is non-inferior to Typbar typhoid conjugate vaccine, a...

HTML version PDF version  Print abstract

 Typhoid
Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study

Published on 26/06/2025 |  Original article (Full-text)  | Pial, Rejwana Haque et al. | Vaccine 2025; 60(In progress): 127304 1 min.

Typhoid fever remains a major public health threat to Low- and Middle-Income (LMIC) countries. The typhoid conjugate vaccine (TCV) is a promising vaccine platform to avert the disease as they elicit sufficient immune response in both adults and children. However, data on long-lasting immune response...

HTML version PDF version  Print abstract